ReviewInternational journal of molecular sciences2019
Gut Microbiome: A Promising Biomarker for Immunotherapy in Colorectal Cancer.
Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 1 synthesis or guideline pooled it, 116 citations in OpenAlex.
- MicroRNAs that regulate PTEN as potential biomarkers in colorectal cancer: a systematic review.Journal of cancer research and clinical oncology · 2020Pooled it
- Harnessing the gut microbiome for improved immune checkpoint inhibition in colorectal cancer immunotherapy: a narrative Review.Clinical and experimental medicine · 2026Review
- CoDaLoMic: An R package for modeling microbiome compositional and longitudinal data.PLoS computational biology · 2026Article
- Intravesical mycobacteria reshape bladder and gut microbiota in a murine bladder cancer model.NPJ biofilms and microbiomes · 2026Article
- The specific hallmarks, emerging roles, key mechanisms, and clinical applications of intra-tumoral microbiota in human cancers.Genes & diseases · 2026Review
- From chaos to order: optimizing fecal microbiota transplantation for enhanced immune checkpoint inhibitors efficacy.Gut microbes · 2025Review
- Intratumoral microbial community profiling identifies clinicomolecular and prognostic subtypes of colorectal cancer liver metastasis.NPJ precision oncology · 2025Article
- Integrating neuroscience and oncology: neuroimmune crosstalk in the initiation and progression of digestive system tumors.Molecular cancer · 2025Review
- Neuro-immune crosstalk in cancer: mechanisms and therapeutic implications.Signal transduction and targeted therapy · 2025Review
- The coadministration of Lactobacillus probiotic augments the antitumor effect of telmisartan in rats.AMB Express · 2025Article
- Bioactive nanomotor enabling efficient intestinal barrier penetration for colorectal cancer therapy.Nature communications · 2025Article
- Comparative microbiome analysis of paired mucosal and fecal samples in Korean colorectal cancer patients.Frontiers in oncology · 2025Article
- The oncobiome; what, so what, now what?Microbiome research reports · 2025Review
- Research progress on fecal microbiota transplantation in tumor prevention and treatment.Open life sciences · 2025Review
- Targeting CD200 in Breast Cancer: Opportunities and Challenges in Immunotherapeutic Strategies.International journal of molecular sciences · 2024Review
- Dysbiosis promotes recurrence of adenomatous polyps in the distal colorectum.World journal of gastrointestinal oncology · 2024Article
- Postbiotics as Adjuvant Therapy in Cancer Care.Nutrients · 2024Review
- Investigating the effect of Fusobacterium nucleatum on the aggressive behavior of cancer-associated fibroblasts in colorectal cancer.Discover oncology · 2024Article
- Microbiome bacterial influencers of host immunity and response to immunotherapy.Cell reports. Medicine · 2024Review
- Exploring the Potential of Humoral Immune Response to CommensalBiomedicines · 2024Review
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Research has been driven towards finding therapy predictive biomarkers for colorectal cancer (CRC) with a special interest in studying the gut microbiome. Gut microbiome acts not only as a barrier to prevent bacterial invasion and infection, but it also affects the efficacy of hematopoietic-cell transplantation, chemotherapy, and immunotherapy. Recently, immunotherapy, which potentiates the host immune system, has revolutionized cancer therapy in general and CRC treatment specifically by increasing the quality of life and the survival of a subset of patients with this disease. In immunotherapy, the gut microbiome plays an important role in cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blockade, programmed cell death protein 1 (PD-L1) mediation, and T cell stimulation. As such, this review will cover the role of gut microbiome in CRC, summarize approved immunotherapy treatments for CRC, and focus on the potential use of gut microbiome as a biomarker for immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.